Stability of Insulin Lispro in Insulin Infusion Systems
- William D Lougheed, PENG,
- Bernard Zinman, MD,
- Thomas R Strack, MD,
- Linda J Janis, PHD,
- Alexandra B Weymouth,
- Elyse A Bernstein,
- Annette M Korbas and
- Bruce H Frank, PHD
- LTBO (Loyal True Blue & Orange) Research Institute Richmond Hill, Ontario, Canada
- Samuel Lunenfeld Research Institute, University of Toronto Toronto, Ontario, Canada
- Eli Lilly Canadas Toronto, Ontario, Canada
- Lilly Research Laboratories Indianapolis, Indiana
- Address correspondence and reprint requests to William D. Lougheed, PEng, Director of Research, Loyal True Blue & Orange Research Institute, 11181 Yonge St., Richmond Hill, Ontario L4S 1L2, Canada.
OBJECTIVE To test stability of insulin lispro in two insulin infusion systems over 48 h.
RESEARCH DESIGN AND METHODS We used reverse-phase and size-exclusion high-performance liquid chromatography (HPLC) to determine the purity, potency, and degree of polymerization of U100 insulin lispro (Humalog) after 24- and 48-h pump cycles conducted at 37°C in five Disetronic H-TRON V100 and five MiniMed 504 pumps. Pumps were set to deliver a basal rate of 0.5 U/h and 6-U boluses at t = 0, 4, 8, 24, 24.5, 28.5, 32.5, and 48 h during each cycle. The effluent was collected into 1-ml vials, pooled at 24 or 48 h, and stored at 4°C until assay. After each 48-h run period of insulin delivery, assays for potency, polymer, and purity were performed on the pooled samples from each individual cycle. m-cresol content and the pooled reservoir content were assayed in the 48-h pooled samples.
RESULTS Insulin lispro retained full HPLC potency (Δ ≤ 4%) at 48 h, with no degradation of insulin lispro to des-amidoinsulin forms (24 or 48 h). No increase in pumped insulin polymer concentration was observed following 24 h of pump flow. Nonsignificant increases of ≤0.09% (Disetronic) and ≤0.15% (MiniMed) from initial concentrations of 0.18% (polymer divided by total insulin) were detected in three of five pump cycles at 48 h when compared with 37°C paired controls. Nonsignificant decreases (<5 and 10%, Disetronic and MiniMed, respectively) of m-cresol content occurred in both systems following 48 h storage in each device, but sterility was not compromised by this decrease (initial m-cresol concentration, 3.15 mg/ml). Pump performance was without mechanical or electrical fault throughout the study Basal and bolus insulin delivery was evaluated three times daily and remained as expected. Occlusion of catheters by insulin precipitation did not occur, and no change in pH was observed following delivery.
CONCLUSIONS We conclude that insulin lispro is suitable for prolonged infusion in these two medical devices when syringes and catheters are replaced at 48-h intervals.
- Received October 7, 1996.
- Revision received March 19, 1997.
- Accepted March 19, 1997.
- Copyright © 1997 by the American Diabetes Association